(Press-News.org) New data from the University of Washington's Alcohol and Drug Abuse Institute indicates increases in heroin availability, abuse and deaths across the state, particularly among young adults ages 18-29. These increases are concerning because of the high risks of overdose and contracting infectious diseases associated with heroin use.
Police drug evidence testing, particularly in 2011 and 2012, points to dramatic increases in heroin. The largest increases were outside of metropolitan areas; the number of pieces of police evidence positive for heroin totaled 842 in 2007 and increased to 2,251in 2012 statewide.
"We are hearing about heroin as a major and increasing problem from law enforcement across Washington in 2012," reports Dave Rodriguez, director of the Northwest High Intensity Drug Trafficking Areas group, a coordinating center for federal and local law enforcement.
In 2012, 64 percent of people entering publicly funded treatment for the first time were heroin users ranging in age from 18 to 29.
"Opiate addiction is a chronic disease that leads to increased hospitalizations and even death, so we want to provide a scope of interventions and treatment," said Chris Imhoff, director of the Washington State Division of Behavioral Health and Recovery in the Department of Social and Health Services. "For those who become addicted, counseling, medication-assisted treatment and recovery support are proven to save lives and reduce future healthcare costs."
Statewide, the rate of accidental deaths involving heroin and other unspecified opiates increased during the period between 2009 and 2011 compared to the previous decade. In King County, which has data through 2012, heroin- involved deaths increased substantially in 2012 due to increases in deaths among people under the age of 30. Between 1997 and 2012 in King County, almost three-quarters of drug- caused deaths involved heroin and/or a prescription-type opiate.
"All opiate overdoses are preventable and many can be reversed prior to becoming fatal if medical aid is sought, "said Dr. Daniel Lessler, the chief medical officer of Washington State's Health Care Authority. "Anyone at risk for having or anticipating an opiate overdose can be prescribed the antidote naloxone in Washington. It is intended for people at risk of an overdose whether they are taking opiate pain medicines or are dealing with opiate addictions."
"People need to be aware of the 911 Overdose Good Samaritan law that provides legal immunity from prosecution for drug possession charges to an overdose victim and anyone who seeks medical help during an overdose," said Caleb Banta-Green, author of the report and a researcher at the Alcohol and Drug Abuse Institute at the University of Washington. "We are continually increasing education and services to try to prevent fatal overdoses. The general public, as well as law enforcement and health care professionals, can learn more at http://www.stopoverdose.org."
###
For the full report on opiate trends visit http://adai.uw.edu/pubs/InfoBriefs/ADAI-IB-2013-02.pdf
Heroin availability increasing across Washington state
New data reveals rise in drug's use among young adults
2013-06-12
ELSE PRESS RELEASES FROM THIS DATE:
EULAR 2013 highlights
2013-06-12
Madrid, Spain, 12 June 2013: The launch of the European Rheumatology Research Foundation (ERRF) was today announced at EULAR 2013, the Annual Congress of the European League Against Rheumatism.
The European Rheumatology Research Foundation (ERRF) is an independent, non-profit body devoted to promoting research in rheumatic and musculoskeletal diseases (RMDs). The ERRF supports high-quality, peer-reviewed research by raising funds from commercial and non-commercial donors. The ERRF aims to support basic and applied research in order to reduce the burden of disease for ...
Significant improvements in psoriatic arthritis with ustekinumab
2013-06-12
Madrid, Spain, 12 June 2013: New PSUMMIT 2* data first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, further demonstrate the efficacy of ustekinumab in Psoriatic Arthritis (PsA).
Anti-TNF naïve and anti-TNF-experienced patients randomised to one of two ustekinumab doses (45mg or 90mg) demonstrated significant and sustained improvements in the signs and symptoms of PsA, with favourable safety profiles.
PsA is a chronic inflammatory arthritis associated with psoriasis which significantly impacts health-related quality of life ...
Patients use OTC NSAIDs even when they have a high risk of serious side effects
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that one in eight patients at risk of developing a serious adverse drug event (ADE) is taking over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat a musculoskeletal complaint.
Of these high risk OTC NSAID users, over one-third had taken the medication for more than 7 days, and 3% had exceeded the maximum recommended daily dosage.
Patients were considered at high risk of a serious ADE from OTC ...
Brodalumab demonstrates significant clinical response in psoriatic arthritis
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that treatment with brodalumab demonstrates significant clinical response and an acceptable safety profile in subjects with psoriatic arthritis (PsA).
PsA is a chronic inflammatory arthritis associated with psoriasis which significantly impacts health-related quality of life in patients, and increases risk of co-morbid cardiovascular and gastrointestinal diseases.2 Psoriasis occurs in 2-3% of the population, with PsA occurring in ...
'Fast track' approach to giant cell arteritis significantly reduces risk of blindness
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that rapid evaluation for Giant Cell Arteritis (GCA) by Color Doppler Ultrasound (CDUS) followed by immediate initiation of treatment (if required) significantly reduces permanent vision loss.
Of the patients evaluated by the ''fast track'' principle from March 2010 to December 2012, 11.1% had transient visual manifestations, and none went on to suffer from permanent visual loss.
GCA is a condition in which medium and large-size arteries, ...
CHERISH trial demonstrates efficacy of tocilizumab in juvenile idiopathic arthritis
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in children with polyarticular Juvenile Idiopathic Arthritis (pcJIA).
Tocilizumab is a humanized recombinant antibody, which blocks the receptors where interleukin-6 (IL-6) attaches to the surface of cells. When IL-6 is unable to attach to these cells, they are prevented from driving inflammation. Elevated serum and joint fluid IL-6 levels ...
Abatacept as effective as adalimumab in rheumatoid arthritis
2013-06-12
Madrid, Spain, 12 June 2013: Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA).
AMPLE, the first two-year head-to-head biologics trial, was comprised of 646 biologic-naïve patients with active rheumatoid arthritis (RA) equally randomised to either ABA or ADA, with a stable dose of methotrexate (MTX). 79.2% (252 of 318) ABA patients and 74.7% (245 of 328) ADA patients completed the trial.
RA is a ...
Long-term apremilast demonstrates continued efficacy in patients with psoriatic arthritis
2013-06-12
Madrid, Spain, 12 June 2013: New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks. For patients who completed 52 weeks of the study, up to 65% achieved ACR20* response rates. Also, apremilast continued to be well tolerated with an acceptable longer-term safety profile.
Apremilast is a novel, oral small-molecule inhibitor of phosphodiesterase 4 (PDE4). It works as an anti-inflammatory ...
New method successfully scores joint damage in rheumatoid arthritis
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrates the efficacy of the ARASHI method at evaluating radiographic (X-ray) joint damage in RA.
The study validated the use of ARASHI to assess joint damage in RA, and clarified the pattern of progression of damage during two-year TNF-blocking therapies. In addition to concluding the success of the scoring method, the data also showed that hip and knee joints with pre-existing damage were predisposed to continue destruction, even during ...
RA patients define ideal online tool for physical activity
2013-06-12
Madrid, Spain, 12 June 2013: Results of the first study involving RA patients in the development of an internet-based physical activity intervention were presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism.
These data show that seven categories are crucial for the adoption and maintenance of PA: personal incentives, personal mastering, information adapted to the Rheumatoid Arthritis (RA) condition, peer support, professional coaching, physical environment and resources, and societal support/financial assistance.
RA is a chronic autoimmune ...
LAST 30 PRESS RELEASES:
An innovative system that dehydrates fruit without heat
The Optica Foundation names Cara Green Executive Director of Development
Is the 'love hormone,' oxytocin, also the 'friendship hormone'?
Global Virus Network reaffirms support for mRNA vaccines and collaborative vaccine research
Unpacking chaos to protect your morning coffee
Planets without water could still produce certain liquids, a new study finds
Researchers identify key biomarkers for chronic fatigue syndrome
Surprisingly diverse innovations led to dramatically cheaper solar panels
Lab-made sugar-coated particle blocks Covid-19 infection — Possible new treatment on the horizon
Rice’s dean of engineering and computing building new software infrastructure for evolutionary biology
Researchers discover all-new antifungal drug candidate in McMaster’s greenhouse
New quality control for ‘wonder material’ graphene oxide is cheapest and fastest yet
How organic matter traps water in soil — even in the driest conditions
Cancer center taps UTA expert for survivor health study
Big gains in type 1 diabetes glucose-control management in recent years
Researchers unlock safer RNA therapies for inflammatory diseases
New gene linked to aggressive, treatment-resistant prostate cancer
Why oxytocin treatments for social behavior are inconsistent
The ISSCR releases targeted update to the guidelines for stem cell research and clinical translation
In utero brain surgery for Vein of Galen Malformation shows continued promise in new JAMA report
Dollar stores’ food options may not be hurting American diets overall
Georgia and Ukraine launch national Reproducibility Networks with support from the TIER2 project
Under-the-skin electrode allows for real-world epilepsy tracking
Livestock played a role in prehistoric plague infections
Provision of abortion medications using online asynchronous telemedicine under shield laws in the US
GLP-1 receptor agonists and sight-threatening ophthalmic complications in patients with type 2 diabetes
Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes
Trends and disparities in technology use and glycemic control in type 1 diabetes
Why these hairy caterpillars swarm every decade – then vanish without a trace
Kennesaw State physics professor receives three-year grant to create simulations for particle colliders
[Press-News.org] Heroin availability increasing across Washington stateNew data reveals rise in drug's use among young adults